New treatments for asthma: The role of leukotriene modifier agents

Journal of the National Medical Association

Volumn 91, Issue SUPPL., 1999, Pages

  Valacer, David J ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Asthma; Inhaled corticosteroid; Leukotriene modifier

Indexed keywords

ACETIC ACID DERIVATIVE; ANTIASTHMATIC AGENT; DRUG DERIVATIVE; HYDROXYUREA; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLINE DERIVATIVE; TOLUENESULFONIC ACID DERIVATIVE; ZAFIRLUKAST; ZILEUTON;

ASTHMA; DRUG SCREENING; EXERCISE INDUCED ASTHMA; HUMAN; REVIEW; TREATMENT OUTCOME;

ACETATES; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTHMA; ASTHMA, EXERCISE-INDUCED; DRUG EVALUATION; HUMANS; HYDROXYUREA; LEUKOTRIENE ANTAGONISTS; QUINOLINES; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 0033416378     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983;220:568-575.
2. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol. 1996;98:1-13.
3. Henderson WR Jr. Role of leukotrienes in asthma. Ann Allergy. 1994;72:272-278.
4. 4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis. 1982;126:449-451.
5. Israel E, Cohn J, Dubé L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. JAMA. 1996;275:931-936.
6. Liu MC, Dubé M, Lancaster J, and the Zileuton Study Group. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol. 1996;98:859-871.
7. Kane GC, Pollice M, Kim C-J, Cohn J, Dworski RT, Murray JJ, et al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol. 1996;97:646-654.
8. O'Connor BJ, Godard P, Dubé LM, Swanson LJ, Rountree LV, and the European Zileuton Study Group. The effect of a 5-lipoxygenase inhibitor, zileuton, plus low-dose inhaled beclomethasone compared to higher dose beclomethasone alone in patients with asthma. Am J Respir Crit Care Med. 1997;153:A803 [Abstract].
9. 4 after exercise challenge in children with asthma. J Allergy Clin Immunol. 1992; 89:1111-1119.
10. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med. 1996;153:931-935.
11. 4 receptor antagonist in subjects with bronchial asthma. Am J Respir Crit Care Med. 1994;150:618-623.
12. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonucelli CM. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clin Therapeut. 1997;19: 675-690.
13. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. Ann Intern Med. 1997;126:177-183.
14. Nathan RA, Glass M, Snader L. Effects of 13 weeks of treatment with ICI 204,219 (Accolate™) or cromolyn sodium (Intal®) in patients with mild to moderate asthma. J Allergy Clin Immunol. 1995;95:388 [Abstract].
15. Finnerty JP, Wood-Baker R, Thomson H, Holgate ST. Role of cysteinyl-leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204,219, a potent D4 receptor antagonist. Am Rev Respir Dis. 1992;145:746-749.
16. Taylor JK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991;337:690-694.
17. Calhoun WJ. Summary of clinical trials with zafirlukast. Am J Respir Crit Care Med. 1998;157:S238-S246.
18. Calhoun WJ, Williams KL, Simonson SG, Lavins BJ. Effect of zafirlukast (Accolate) on cellular mediators of inflammation. Am J Respir Crit Care Med. 1998;157:1381-1389.
19. Laitinen LA, Zetterström O, Holgate ST, Binks SM, Whitney JG. Effects of Accolate™ (zafirlukast; 20 mg bd) in permitting reduced therapy with inhaled steroids: a multicenter trial in patients with doses of inhaled steroid optimised between 800 and 2000 mcg per day. Allergy. 1995;50(suppl 26):320 [Abstract].
20. Bateman ED, Holgate ST, Binks SM, Tams IP. A multicentre study to assess the steroid-sparing potential of Accolate™ (zafirlukast; 20 mg bd). Allergy. 1995;50(suppl 26):320 [Abstract].
21. Nayak AS, Anderson PJ, Charous KL, Williams KL, Miller CJ, Bonucelli M, et al. Addition of zafirlukast compared with a doubled-dosage of inhaled corticosteroids in asthmatic patients with symptoms on inhaled corticosteroids. Eur Respir J. 1998;12(suppl 28):361S [Abstract].
22. Virchow JC, Hassall SM, Summerton L, Harris A, Klink RK. Improved asthma control over 6 weeks with Accolate;® (zafirlukast) in patients with high-dose inhaled corticosteroids. J Invest Med. 1997;45:286A [Abstract].
23. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB, for the Montelukast Clinical Research Study Group. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med. 1998;158:1213-1230.
24. 1 receptor antagonist, improves the signs and symptoms of asthma over one year of treatment. Eur Respir J. 1997;10(suppl 25):437S [Abstract].
25. Noonan G, Reiss TF, Shingo S, Nguyen HH, Knorr B, and the Montelukast Adult and Pediatric Study Groups. Montelukast (MK-0476) maintains long-term asthma control in adult and pediatric patients (aged =6 years). Am J Respir Crit Care Med. 1999;159(3, pt 2):A640 [Abstract].
26. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Piñeiro A, Wei LX, et al, for the Montelukast/Beclomethasone Study Group. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Ann Intern Med. 1999;130:487-495.
27. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6-14-year-old children: a randomized, double-blind trial. JAMA. 1998;279: 1181-1186.
28. Leff J, Busse W, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998;339: 147-152.
29. Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med. 1994;149:953-959.
30. Leff JA, Israel E, Noonan MJ, Finn AF, Godard P, Lofdahl CG, et al. Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability. Am J Respir Crit Care Med 1997;155:A976 [Abstract].
31. Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seidenberg, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6-14-year-old children with asthma. J Pediatr. 1998;133:424-428.
32. Villaran C, O'Neill S, Helbling A, van Noord JA, Lee T, Chucalin AG, et al. Montelukast compared with salmeterol in the treatment of exercise-induced asthma (EIA). Eur Respir J. 1998;12:(suppl 28):361S [Abstract].
33. Holland S, Shahane A, Rogers JD, Porras A, Grasing K, et al. Metabolism of montelukast (M) is increased by multiple doses of phenobarbital (P). Clin Pharmacol Ther. 1998;63:231A [Abstract].
34. Vargo DL, Yeh C, Lasseter K, Birmingham BK. Effect of zafirlukast on prothrombin time and area under the curve of warfarin in healthy men. J Clin Pharmacol. 1997;37:870 [Abstract].
35. Awni WM, Hussein Z, Granneman GR, Patterson KJ, Dubé LM, Cavanaugh JH. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clin Pharmacokinet. 1995;29(suppl 2):67-76.
36. Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dubé LM, Awni WM. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet. 1995;29(suppl 2):77-83.